Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
Last trade$1.98
Day change+$0.005 (+0.25%)
Day range$1.86 – $2.05
Volume837,492
Market cap$166M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$166.39M
Price / earnings
—
Price / book
5.4×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.83×
Profitability
Earnings per share
-$1.00
Return on assets
-78.85%
Return on equity
-273.05%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.3×
Quick ratio
6.3×
Cash ratio
0.59×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$78.36M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ELDN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.91M
$4.64M
$3.98M
$3.99M
$4.1M
$4.46M
$4.43M
$6.77M
Research and development
$17.76M
$18.23M
$17.2M
$17.49M
$14.97M
$20.28M
$13.53M
$17.93M
Total operating expenses
$21.67M
$22.87M
$21.18M
$21.48M
$19.07M
$24.73M
$17.96M
$24.7M
Operating income
-$21.67M
-$22.87M
-$21.18M
-$21.48M
-$19.07M
-$24.73M
-$17.96M
-$24.7M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$3.93M
-$31.63M
-$39.03M
-$10.41M
-$17.46M
-$11.22M
-$6.5M
-$44.19M
Income taxes
$0
$0
$0
$35K
$0
$0
$0
$431K
Net income
-$3.93M
-$31.63M
-$39.03M
-$10.45M
-$17.46M
-$11.22M
-$6.5M
-$44.62M
Net income attributable to common shareholders
-$3.79M
-$30.24M
-$36.94M
-$13.13M
-$16.13M
-$10.36M
-$6M
-$41.74M
EBITDA
-$21.67M
-$22.87M
-$21.18M
-$21.48M
-$19.07M
-$24.73M
-$17.96M
-$24.7M
Basic earnings per share
-$0.03
-$0.27
-$0.33
-$0.14
-$0.21
-$0.13
-$0.08
-$0.60
Diluted earnings per share
-$0.03
-$0.27
-$0.33
-$0.14
-$0.21
-$0.13
-$0.08
-$0.63
Recent news
Company coverage with links to the original publishers.
Eledon Pharmaceuticals announced updated Phase 2 BESTOW extension study results showing tegoprubart-treated kidney transplant patients maintained significantly higher kidney function (71 vs. 58 mL/min/1.73 m² eGFR at 24 months) compared to tacrolimus, with zero rejections beyond six months versus seven in the tacrolimus arm. The FDA granted Fast Track designation to tegoprubart for kidney transplant rejection prevention, and the company plans to initiate the Phase 3 LEGACY trial in Q4 2026.
Eledon Pharmaceuticals reported positive Phase 2 BESTOW trial results for tegoprubart, demonstrating favorable safety in kidney transplant prevention, and raised $57.5 million in financing to advance transplantation programs.
Eledon Pharmaceuticals announced positive Phase 2 trial results for tegoprubart, a potential new immunosuppression treatment for kidney transplant patients, showing promising safety and efficacy with reduced side effects compared to tacrolimus.
Eledon Pharmaceuticals will present topline results from its Phase 2 BESTOW trial evaluating tegoprubart for kidney transplant rejection prevention at the American Society of Nephrology's Kidney Week 2025 in Houston, TX.
Eledon Pharmaceuticals' CEO will participate in a fireside chat at the Cantor Global Healthcare Conference, discussing the company's investigational product tegoprubart, an anti-CD40L antibody targeting immune-modulating therapies for conditions like kidney transplantation and ALS.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.